Relevium Signs Exclusivity Agreement With SOSCannabis.com for
Reimbursement for Pediatric Patients
MONTREAL, Canada -- July 10, 2019 -- InvestorsHub NewsWire --
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt:
“6BX”) (the “Company” or
“Relevium”), announced today it has executed an exclusivity
agreement to partner with SOS cannabis Inc. (“SOSCannabis”), which
will provide pediatric customers with the ability to obtain free
legal representation to seek reimbursement for the costs of medical
cannabinoid therapy from different government agencies for the
treatment of medical conditions for pediatric patients.
The partnership agreement will provide
Relevium’s pediatric customers with access to an experienced legal
and case management team, who will prepare the case file and seek
retroactive and prospective reimbursement for parents of pediatric
patients at no cost. The agreement provides Relevium with a unique
advantage in terms of its business development strategy and first
to market positioning in terms of pediatric applications.
Mr. Aurelio Useche, CEO of Relevium stated: “As we prepare to
enter the pediatric endo-medicinal market in Canada with an initial
ten (10) CannaKids® formulated products, not
only are we providing parents with a natural alternative and/or
health support mechanism, but now we are able to provide them with
the ability to seek reimbursement from governmental agencies
without any costs,” Mr. Useche stated
further: “We are extremely happy to work with a team of
caring legal professionals that can represent our customers in
minimizing the financial burden of cannabinoid therapy.”
Maitre Robert Astell, President of SOSCannabis.com stated “We are
delighted to welcome Relevium into our family of medicinal
cannabinoid therapy suppliers. The focus and quest of Relevium in
terms of pediatric patients is admirable and we look forward to
onboarding parents into our fully-automated registration platform
and to provide them with the state-of-the-art case management
service in fulfilling their need for economic assistance in
providing natural medicine to their children.”
Tracy Ryan, CEO of Cannakids® stated: “For years
patients have struggled with the high expenses that come along with
using cannabis as a medicine. Especially parents to sick children
who often lose their jobs due to countless hospital stays and
doctor’s appointments. This new opportunity for families is a major
step in the right direction. We are elated that more will now have
the opportunity to afford this powerful, non-toxic option that we
have seen bring unimaginable relief to patients on a global
scale.”
About S.O.S Cannabis
SOSCannabis.com is a multi-disciplinary
law firm headquartered in Québec, Canada whose objective is to help
people that use medical cannabis prescribed by a doctor to seek
retroactive and prospective monetary reimbursement through claims
made to governmental organizations. SOS Cannabis also provides
referral services to a network of medical professionals and medical
cannabis suppliers. The company counts with an experienced legal
and administrative team to support medical claims with the
provincial and federal governments.
About Cannakids®
CannaKids.org is a privately held company
that has provided CO2 extracted, lab tested cannabis oil products
to thousands of patients over the past 4 years. Using nurse guided
assistance, the brand has been synonymous with some of the most
recognized patient success stories in the world.
About Relevium Technologies
Relevium is a publicly-traded company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operation of brands and businesses in
the health and wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly owned subsidiaries:
BGX E-Health LLC (BGX),
based in Orlando, Florida, markets dietary supplements,
nutraceuticals, sports nutrition and cosmeceuticals primarily
through its Bioganix® brand portfolio in the US and Europe.
Relevium’s premium brands are sold at some of the world’s largest
retailers including Walmart.com and Amazon.com.
Biocannabix Health
Corporation (BCX), based in Montreal, Quebec, is a
biopharma nutraceutical company focused on delivering pediatric
endo-medicinal nutraceuticals for cannabinoid therapy.
Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements
This release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian and United States securities laws. All
statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions or expectations of future
performance, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as “intends” or “anticipates”, or variations of
such words and phrases or statements that certain actions, events
or results “may”, “could”, “should”, or “would” occur.
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek to rely on the
applicable safe harbor.
On Behalf of the Board of Directors
RELEVIUM
TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release:
Tel: +1.888.528.8687
Email: investors@releviumcorp.com Website: www.releviumtechnologies.com
https://www.facebook.com/releviumcorp/
https://ca.linkedin.com/company/relevium-technologies-inc-
https://twitter.com/releviumcorp?lang=en
Relevium Technologies (CE) (USOTC:RLLVF)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Relevium Technologies (CE) (USOTC:RLLVF)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025